Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why

Atossa Genetics Inc. (NASDAQ:ATOS)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.82 and traded as low as $0.6350. Atossa Genetics shares last traded at $0.6530, with a volume of 900,864 shares traded.

Analysts Set New Price Targets

A number of research firms have recently commented on ATOS. Ascendiant Capital Markets lifted their price target on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Zacks Research downgraded shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Atossa Genetics currently has a consensus rating of “Hold” and a consensus target price of $6.33.

Atossa Genetics Price Performance

The firm has a 50 day moving average of $0.75 and a 200-day moving average of $0.82. The stock has a market capitalization of $84.35 million, a P/E ratio of -2.72 and a beta of 1.09.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). As a group, equities analysts expect that Atossa Genetics Inc. will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Genetics

A number of hedge funds have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd acquired a new position in Atossa Genetics during the second quarter worth $321,000. Squarepoint Ops LLC boosted its stake in Atossa Genetics by 39.9% in the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after purchasing an additional 72,235 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics during the second quarter worth $26,000. Finally, Bank of America Corp DE raised its stake in shares of Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after acquiring an additional 35,629 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.